| Company Name: |
BOC Sciences |
| Tel: |
16314854226 |
| Email: |
info@bocsci.com |
| Company Name: |
Energy Chemical |
| Tel: |
021-58432009 400-005-6266 |
| Email: |
marketing@energy-chemical.com |
|
| | 4-[[2-[[(2-Cyanophenyl)methyl]thio]-4-oxothieno[3,2-d]pyrimidin-3(4H)-yl]methyl]benzoic acid Basic information |
| | 4-[[2-[[(2-Cyanophenyl)methyl]thio]-4-oxothieno[3,2-d]pyrimidin-3(4H)-yl]methyl]benzoic acid Chemical Properties |
| Boiling point | 694.0±65.0 °C(Predicted) | | density | 1.41±0.1 g/cm3(Predicted) | | storage temp. | 2-8°C | | solubility | DMSO: 20mg/mL, clear | | pka | 4.21±0.10(Predicted) | | form | powder | | color | white to beige | | InChIKey | UWWSCLNCHCROLL-UHFFFAOYSA-N | | SMILES | OC(C1=CC=C(CN2C(SCC3=CC=CC=C3C#N)=NC(C=CS4)=C4C2=O)C=C1)=O |
| WGK Germany | WGK 3 | | Storage Class | 11 - Combustible Solids | | Hazard Classifications | Aquatic Chronic 4 |
| | 4-[[2-[[(2-Cyanophenyl)methyl]thio]-4-oxothieno[3,2-d]pyrimidin-3(4H)-yl]methyl]benzoic acid Usage And Synthesis |
| Uses | SPL 334 is an S-Nitrosoglutathione Reductase inhibitor. | | Biological Activity | SPL-334 is an inhibitor of S-Nitrosoglutathione reductase (GSNOR), the enzyme responsible for regulating cellular concentrations of S-Nitrosoglutathione (GSNO), which plays a critical role in nitric oxide signaling in the respiratory tract. In a mouse model of allergic airway inflammation, SPL-334 reduced airway hyperreactivity, and in a bleomycin injury model of interstitial lung disease, SPL-334 reduced lung inflammation and fibrosis. Studies for treatment of asthma, idiopathic pulmonary fibrosis (IPF), and inflammation are ongoing. | | in vivo | SPL-334 (0.1-1 mg/kg; Intranasal administration; daily, for 7 d; BALB/c recipient mice with DO11.10 CD4+ Th2 xenograft) causes a reduction in allergic airway inflammation[1]. | Animal Model: | BALB/c recipient mice with DO11.10 CD4+ Th2 xenograft[1] | | Dosage: | 0.1 or 1 mg/kg | | Administration: | Intranasal administration; daily, for 7 days | | Result: | Caused a significant reduction in the influx of lymphocytes and eosinophils into the airways and the level of EPO in the BALF.
Reduced the number of OVA-specific T cells and eosinophils during allergic airway inflammation.
Reduced in peribronchial inflammation and mucus secretion during airway inflammation.
|
|
| | 4-[[2-[[(2-Cyanophenyl)methyl]thio]-4-oxothieno[3,2-d]pyrimidin-3(4H)-yl]methyl]benzoic acid Preparation Products And Raw materials |
|